查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1935257

中樞神經系統特異性反義寡核苷酸市場（依藥物、適應症、通路和地區分類）

CNS Specific Antisense Oligonucleotide Market, By Drug, By Indication, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

中樞神經系統特異性反義寡核苷酸市場預計在 2026 年達到 32 億美元，預計到 2033 年將達到 61 億美元，2026 年至 2033 年的複合年成長率為 9.8%。

報告覆蓋範圍 報告詳情
基準年： 2025 2026年市場規模： 32億美元
歷史數據時期： 2020年至2024年 預測期： 2026年至2033年
預測期（2026-2033年）複合年成長率： 9.80% 2033 年的預測值： 61億美元

反義寡核苷酸是能夠抑制傳訊RNA（mRNA）表現的合成核酸鏈。它們透過抑制前驅mRNA的剪接，發揮蛋白質修復和修飾等功能。反義寡核苷酸是一種旨在預防神經退化性疾病發生和延緩其進展的新型治療方法。

市場動態

神經退化性疾病的日益普遍是推動中樞神經系統（CNS）特異性反義寡核苷酸市場成長的主要因素。根據老年失智症協會的情況說明書，2018年估計有570萬美國人被診斷出患有老年失智症失智症。此外，用於治療中樞神經系統疾病及相關罕見疾病的豐富產品平臺也預計將推動市場成長。例如，2018年12月，百健（Biogen）和Ionis Pharmaceuticals聯合研發的IONIS-SOD1Rx（BIIB067）完成了I期臨床試驗，預計於2020年上市。

本次調查的主要特點

  • 本報告對中樞神經系統特異性反義寡核苷酸市場進行了詳細分析，以 2017 年為基準年，給出了預測期（2018-2026 年）內的市場規模和復合年成長率（%）。
  • 該報告還重點介紹了各個細分市場的潛在商機，並概述了該市場具有吸引力的投資提案矩陣。
  • 該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
  • 本報告根據以下參數對全球中樞神經系統特異性反義寡核苷酸市場的主要企業進行了分析：公司概況、財務績效、產品系列、市場地位、分銷策略、關鍵發展、策略和未來計劃。
  • 本報告的研究結果將幫助負責人和經營團隊就即將推出的產品、技術升級、市場擴張和行銷策略做出明智的決策。
  • 這份全球中樞神經系統特異性反義寡核苷酸市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
  • 相關人員可以透過各種策略矩陣輕鬆做出決策，這些矩陣用於分析中樞神經系統特異性反義寡核苷酸市場。

目錄

第1章 研究目標與前提條件

  • 調查目的
  • 先決條件
  • 簡稱

第2章 市場概覽

  • 報告概述
    • 市場定義和範圍
  • 執行摘要

第3章 市場動態、監理及趨勢分析

  • 市場動態
  • 影響分析
  • 主要亮點
  • 法規環境
  • 產品上市及核准情況
  • PEST分析
  • 波特分析
  • 市場機遇
  • 法規環境
  • 重大進展
  • 產業趨勢

4. 2020-2033年全球中樞神經系統特異性反義寡核苷酸市場（依藥物類型分類）

  • 已通過核准的
  • 開發中

5. 2020-2033年全球中樞神經系統特異性反義寡核苷酸市場（依適應症分類）

  • 遺傳性轉甲狀腺素蛋白類澱粉沉積症（hATTR）/神經病變
  • 脊髓性肌肉萎縮症
  • 亨丁頓舞蹈症

6. 2020-2033年全球中樞神經系統特異性反義寡核苷酸市場（依通路分類）

  • 醫院藥房
  • 零售藥房
  • 網路藥房

7. 2020-2033年全球中樞神經系統特異性反義寡核苷酸市場（依地區分類）

  • 北美洲
    • 美國
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲國家
  • 歐洲
    • 德國
    • 英國
    • 西班牙
    • 法國
    • 義大利
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • ASEAN
    • 亞太其他地區
  • 中東
    • 海灣合作理事會國家
    • 以色列
    • 其他中東國家
  • 非洲
    • 南非
    • 北非
    • 中非

第8章 競爭情勢

  • Alnylam Pharmaceuticals Inc.
  • Sarepta Therapeutics Inc.
  • Biogen Inc.
  • Ionis Pharmaceuticals Inc.
  • Wave Life Sciences Ltd.
  • Stroke Therapeutic Inc.
  • Dynacure
  • ProQR Therapeutics NV
  • Q-STATE BIOSCIENCES, INC.

第9章 分析師建議

  • 機會
  • 分析師觀點
  • Coherent Opportunity Map

第10章 參考文獻與調查方法

  • 參考
  • 調查方法
  • 關於本公司
簡介目錄
Product Code: CMI2477

CNS Specific Antisense Oligonucleotide Market is estimated to be valued at USD 3,200 Mn in 2026 and is expected to reach USD 6,100 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 3,200 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 9.80% 2033 Value Projection: USD 6,100 Mn

Antisense oligonucleotides are synthetic strings of nucleic acid, which reduce expression of messenger RNA (m-RNA). The function performed by interference with pre m- RNA splicing are restoration of protein and modification of protein. Antisense oligonucleotide is a new approach to treat several neurodegenerative disorders to prevent disease onset or stop disease development.

Market Dynamics

Increasing prevalence of neurodegenerative disease is a major factor driving CNS specific antisense oligonucleotide market growth. According to fact sheet from Alzheimer Association, an estimated around 5.7 million Americans were diagnosed with Alzheimer's dementia in 2018. Moreover, rich product pipeline for the treatment of CNS disorders and rare diseases associated with it is expected to boost the market growth. For instance, in December 2018, Biogen and Ionis Pharmaceuticals product IONIS-SOD1Rx (BIIB067) cleared Phase 1 clinical trial and is expected to be launched by 2020.

Key features of the study

  • This report provides in-depth analysis of the CNS specific antisense oligonucleotide market and provides market size (USD million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global CNS specific antisense oligonucleotide market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., Q-STATE BIOSCIENCES, INC.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global CNS specific antisense oligonucleotide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the CNS specific antisense oligonucleotide market

Market Segmentation

  • Drug Insights (Revenue, USD Mn, 2026 - 2033)
    • Approved
    • Pipeline
  • Indication Insights (Revenue, USD Mn, 2026 - 2033)
    • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
    • Spinal Muscular Atrophy
    • Huntington's Disease
  • Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Regional Insights (Revenue, USD Mn, 2026 - 2033)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
    • North Africa
    • Central Africa
    • South Africa
  • Key Players Insights
    • Alnylam Pharmaceuticals Inc.
    • Sarepta Therapeutics Inc.
    • Biogen Inc.
    • Ionis Pharmaceuticals Inc.
    • Wave Life Sciences Ltd.
    • Stroke Therapeutic Inc.
    • Dynacure
    • ProQR Therapeutics N.V.
    • Q-STATE BIOSCIENCES, INC.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global CNS Specific Antisense Oligonucleotide Market, By Drug
    • Global CNS Specific Antisense Oligonucleotide Market, By Indication
    • Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel
    • Global CNS Specific Antisense Oligonucleotide Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Market Opportunities
  • Regulatory Scenario
  • Key Developments
  • Industry Trend

4. Global CNS Specific Antisense Oligonucleotide Market, By Drug, 2020-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Approved
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Pipeline
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

5. Global CNS Specific Antisense Oligonucleotide Market, By Indication, 2020-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Spinal Muscular Atrophy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Huntington's Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

6. Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel Type, 2020-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Hospital Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Retail Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Online Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

7. Global CNS Specific Antisense Oligonucleotide Market, By Region, 2020 - 2033, Value (USD Mn)

  • Introduction
    • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Mn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
      • South Africa
      • North Africa
      • Central Africa

8. Competitive Landscape

  • Alnylam Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sarepta Therapeutics Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Biogen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Ionis Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Wave Life Sciences Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Stroke Therapeutic Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dynacure
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • ProQR Therapeutics N.V.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Q-STATE BIOSCIENCES, INC.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

10. References and Research Methodology

  • References
  • Research Methodology
  • About us